close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tharimmune, Inc. - Common Stock (NQ:THAR)

3.160 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tharimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
What's Going On With Tharimmune Shares Monday?
Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver... 
Via Benzinga
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Via ACCESSWIRE
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Via ACCESSWIRE
10 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
THAR Stock Earnings: Tharimmune Reported Results for Q2 2024
Tharimmune just reported results for the second quarter of 2024. 
Via InvestorPlace
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
 
Via Benzinga
S&P 500 Edges Lower; US Crude Oil Inventories Fall
 
Via Benzinga
Topics Stocks
What's Going On With Tharimmune Shares Wednesday?
Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher on Wednesday after the company announced it received overall positive feedback from the European Medicines Agency (EMA) on its TH104 clinical... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results
 
Via Benzinga
Topics Stocks
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Via ACCESSWIRE
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Via ACCESSWIRE
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Via ACCESSWIRE
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
Via ACCESSWIRE
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Announces $2.08 Million Private Placement
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Why Tharimmune (THAR) Shares Are Getting Hammered
Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement. 
Via Benzinga
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune to Present at 2024 BIO International Convention
Via ACCESSWIRE
Why Is Verastem (VSTM) Stock Down 62% Today?
Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today